In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Combion Inc.

Division of Incyte Corp.

Latest From Combion Inc.

Step-Ups in DNA Chip IPOs

Companies focused on DNA chips have been perennial favorites of the IPO market, from Affymetrix Inc.'s $90 million IPO in April 1996 to Nanogen Inc.'s $64 million offering, Affymetrix, Hyseq Inc., Vysis Inc. and Nanogen Inc. all received pre-money valuations about 3-4 times the total amount paid in by private investors prior to IPO, and post-money multiples of about 4.5 to 5.5.
BioPharmaceutical Medical Device

Getting to the Ultimate Database

Affymetrix is suing Incyte--the latest manifestation of how two apparently different businesses, based on very different technologies, are going to have to go head-to-head, competitively. The goal: the ultimate genomics database.
BioPharmaceutical Strategy

DNA-Chips in Genomics

DNA chips have application as high-througput assays to determine the function of genes. The chips can also speed positional cloning. Development agreements with pharmaceutical partners should illuminate the DNA chips’ real abilities and applications. Coupled with strong bioinformatics, gene expression microarrays will produce the next generation of genomic databases.
BioPharmaceutical Platform Technologies

The DNA-Chip in Diagnostics

Over the last 5-years the DNA probe array for diagnostics has moved from concept to market. But opportunities in infectious disease are limited, and the opportunity at the point-of-care is still evolving. Meanwhile, ripe opportunities and big valuations in genomics are luring DNA-chip companies away from diagnostics. Oligonucleotide arrays should have a role to play in linking outcomes to genes in AIDS and cancer.
Medical Device Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Incyte Corp.
  • Senior Management
  • Stuart Davidson, Pres.
  • Contact Info
  • Combion Inc.
    Phone: (415) 299-0311
    400 Seaport Ct. Suite 250
    Redwood City, CA 94063